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Abstract
Introduction Treating hyperglycaemia in hospitalized patients has proven to be beneficial, particularly
in those with obstructive vascular disease. In a cohort of patients undergoing resection for oesophageal
carcinoma (a group of patients with severe surgical stress but a low prevalence of vascular disease),
we investigated whether early postoperative hyperglycaemia is associated with increased incidence of
infectious complications and prolonged in-hospital stay.
Methods Postoperative glucose values up to 48 hours after surgery were retrieved for 151 patients
with American Society of Anesthesiologists class I or II who had been previously included in a
randomized trial conducted in a tertiary referral hospital. Multivariate regression analysis was used to
define the independent contribution of possible risk factors selected by univariate analysis.
Results In univariate regression analysis, postoperative glucose levels were associated with increased
length of in-hospital stay (P < 0.001) but not with infectious complications (P = 0.21). However,
postoperative glucose concentration was not found to be an independent risk factor for prolonged in-
hospital stay in multivariate analysis (P = 0.20).
Conclusion Our data indicate that postoperative hyperglycaemia is more likely to be a risk marker than
a risk factor in patients undergoing highly invasive surgery for oesophageal cancer. We hypothesize
that patients with a low prevalence of vascular disease may benefit less from intensive insulin therapy.
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Introduction
Until recently hyperglycaemia after surgery was considered to
be a benign phenomenon. However, in a landmark study, van
den Berghe and coworkers [1] showed that treating transient
postoperative hyperglycaemia with intensive insulin therapy in
a surgical intensive care unit (ICU) dramatically reduces mor-
tality and morbidity. Strict glucose control (target range
between 4.4 mmol/l and 6.1 mmol/l) was responsible for a
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reduction in both ICU and in-hospital mortality, which was pri-
marily attributed to the prevention of septic complications [1].
The population studied by van den Berghe and coworkers was
diverse but consisted primarily of patients who underwent car-
diac surgery (63%). Others have found beneficial effects of
intensive insulin therapy in patients with obstructive vascular
disease such as acute myocardial infarction and acute stroke,
and in those who have undergone cardiovascular bypass sur-
gery [2-7]. Strict glucose control is relatively time consuming
for ICU personnel because of frequent glucose monitoring,
and it may be hazardous because of the risk for hypoglycae-
mia. It is therefore important to determine which patient groups
in the ICU are likely to benefit most or least from aggressively
correcting hyperglycaemia.
We investigated whether postoperative hyperglycaemia is a
risk factor for postoperative infections and prolonged in-hospi-
tal stay in a cohort of patients undergoing resection for aden-
ocarcinoma of the oesophagus (i.e. patients with a low
prevalence of risk factors for insulin resistance and cardiovas-
cular disease but who are subject to great postoperative
stress).
Methods
Patients
A total of 220 consecutive patients with adenocarcinoma of
the oesophagus from two university hospitals in Amsterdam
and Rotterdam were included in a previously reported rand-
omized clinical trial investigating differences in short-term and
long-term morbidity and mortality between two surgical
approaches for resection of oesophageal adenocarcinoma
[8]. Classification into American Society of Anesthesiologists
(ASA) class 1 or 2 was a requirement for eligibility in that
study.
Only patients included in Amsterdam were included in the
present analysis (n  = 160), because glucose values were
taken only in a small proportion of the Rotterdam patients. In
nine cases oesophageal resection was cancelled peropera-
tively because of distant dissemination of tumour, leaving 151
patients for this analysis.
Data collection
Glucose values were automatically determined with each arte-
rial blood sample test (Ciba Corning 865; Chiron Diagnostics,
Medford, MA, USA), and were collected retrospectively from
laboratory reports. Forced expiratory volume in 1 s (FEV1)
expressed as percentage of the predicted value corrected for
age and sex, and patient height (to calculate body mass index
[BMI]) were collected retrospectively from preoperative lung
function reports. Insulin use in the first 48 hours after surgery
was determined retrospectively from ICU charts. In the pro-
spective cohort patients were visited at least twice a week by
one of the investigators to score postoperative complications.
Postoperative infections were defined as signs of infection
and positive culture [9]. History of cardiovascular disease,
hypertension, weight loss, ASA class, postoperative occur-
rence of left ventricular failure and length of hospital stay were
determined prospectively [8].
Patients were allowed to eat as they wished until 24 hours
before surgery. Patients with more than 10% weight loss in the
year preceding surgery received preoperative enteral tube
feeding. Postoperatively, all patients received continuous tube
feeding through a needle jejunostomy, starting 12–24 hours
postoperatively, with 25 ml/hour tube feeding containing
immunomodulatory nutrients (Impact®; Novartis, Basel, Swit-
serland). As a general rule, patients received 30 ml glucose
5% intravenously during the first 48 hours after surgery and
patients were treated with insulin when glucose values
exceeded 12 mmol/l.
Statistical analysis
For each patient the mean postoperative glucose concentra-
tion was calculated using all available glucose measurements
obtained until 48 hours postoperatively. For further analysis,
mean postoperative glucose concentrations were divided into
quartiles because of nonparametric distribution.
Univariate regression analysis was used to select parameters
associated with infectious complications and length of hospi-
tal stay. Parameters with P < 0.1 in univariate regression anal-
ysis were examined in multivariate analysis to define the
independent contribution of each possible risk factor [10].
Postoperative glucose concentrations were automatically
selected for multivariate analysis because it was the main aim
of the study to determine their relationship with outcome.
Logistic regression analysis was used for infectious complica-
tions, and linear regression analysis was used for length of
stay. Because of nonparametric distribution, length of stay
data were logarithmically transformed before regression
analysis.
Parameters included in the analysis
Age, amount of preoperative weight loss, BMI and FEV1 were
entered into regression analyses as continuous variables.
Postoperative glucose levels, insulin use within 48 hours after
surgery, type of surgical procedure, sex, ASA class, history of
hypertension, coronary artery disease, cardiac valve disease
or arrhythmia, clinical staging of the tumour and presence of
diabetes mellitus were entered as categorical variables.
Results
Preoperative characteristics are summarized in Table 1. At
least one postoperative glucose value could be retraced in
150 out of 151 cases (99%; median 7 glucose values per
patient; range 1–21). A glucose level greater than 6.1 mmol/l
was found in 97% of patients. During the first 48 hours after
surgery, insulin was administrated to four patients with knownAvailable online http://ccforum.com/content/8/6/R437
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diabetes mellitus and to five patients without diabetes mellitus,
but insulin administration could not be retraced in one patient
with known diabetes mellitus. At least one infectious complica-
tion occurred in 55 patients (36%) and more than one infec-
tion occurred in 15 patients (9.9%). Pneumonia occurred in
44 patients, wound infection in 15, urinary tract infection in six
and sepsis in seven. Patients were admitted to the ICU for a
median duration of 3 days (range <24 hours to 71 days). The
median length of stay was 16 days (range 9–154 days). The
incidences of postoperative left ventricular failure (n = 13;
8.6%) and in-hospital death (n = 5; 3.3%) were too low to
allow for regression analysis.
Postoperative glucose levels and postoperative 
infections
According to univariate regression analysis, no association
was found between postoperative glucose levels and infec-
tious complications (P  = 0.21; Fig. 1a) or between insulin
administration and infectious complications (P = 0.37; odds
ratio [OR] 0.5, 95% confidence interval [CI] 0.1–2.4). Param-
eters associated with postoperative infections in univariate
regression analysis were history of cardiac valve disease or
arrhythmia (P = 0.026; OR 11.5, 95% CI 1.35–98.2), FEV1
per 10% increase (P = 0.021; OR 0.78, 95% CI 0.63–0.96;
OR per 10% of expected FEV1), age per 10 years (P = 0.069;
OR 1.39, 95% CI 0.98–1.97) and duration of surgery per hour
(P = 0.059; OR 1.23, 95% CI 0.99–1.52). In the subgroup of
patients with an ICU stay in excess of 5 days, there was no
association between postoperative hyperglycaemia and infec-
tion (P = 0.9 for trend; P = 0.8 by χ2 analysis). Also in multi-
variate analysis, postoperative hyperglycaemia was not found
to be a predictor of postoperative infection (P = 0.28; OR
1.21, 95% CI 0.86–1.72; Table 2). Also, patients with at least
one glucose value in excess of 10 mmol/l were not at greater
risk for infections (data not shown).
Postoperative glucose levels and length of stay
In univariate analysis, a positive association was found
between postoperative hyperglycaemia and length of hospital
stay (P < 0.001; β = 0.053; standard error [SE] of β = 0.014),
but not with insulin administration (P = 0.5; β = -0.56; SE of β
= 0.7). Other parameters associated with length of in-hospital
stay were duration of surgery (P < 0.001; β = 0.050; SE of β
= 0.010), transthoracic procedure (P < 0.001; β = 0.119, SE
Table 1
Other possible risk factors for infection and length of stay
Preoperative parameter Value Missing values (%)
Age in years (mean ± SD) 62.4 ± 10.0 0
Male sex (n [%]) 127 (84.1) 0
ASA 0
Class I (n [%]) 47 (31.1)
Class II (n [%]) 104 (68.9)
History of cardiac valve disease or arrhythmia (n [%]) 7 (4.6) 0.7
History of hypertension (n [%]) 21 (13.9) 0.7
History of coronary artery disease (n [%]) 16 (10.6) 0.7
BMI (mean ± SD) 25.4 ± 3.3 25.8
Percentage of expected FEV1 (mean ± SD) 101 ± 18 18.5
Diabetes mellitus (n [%]) 9 (6.0) 0.7
Preoperative weight loss (kg; mean ± SD) 5.3 ± 6.6 7.9
Clinical staging of tumor 1.3
Stage I (n [%]) 18 (11.9)
Stage II (n [%]) 68 (45.0)
Stage III (n [%]) 58 (38.4)
Stage IV (n [%]) 5 (3.3)
Allocated to transthoracic procedure (n [%]) 78 (51.7%) 0
Duration of surgery (hours; mean ± SD) 5.3 (1.6) 0.7
Insulin use within 48 hours after surgery (n [%]) 9 (6.0%) 9.2
A total of 151 patients were included. ASA, American Society of Anesthesiologists; BMI, body mass index; FEV1, forced expiratory volume in 1 s; 
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of β = 0.032), BMI (P = 0.036; β = 0.013; SE of β = 0.006)
and history of cardiac valve disease or arrhythmia (P = 0.103;
β = 0.130; SE of β = 0.079). After correction for these varia-
bles in multivariate analysis, mean postoperative glucose con-
centration was found not to be an independent risk factor for
prolonged hospital stay (P = 0.20; Table 3). Adding duration
of ICU stay greater than 5 days as an interaction term was not
statistically significant (P = 0.12).
Discussion
In a cohort of patients undergoing highly invasive surgery for
oesophageal cancer, we found that postoperative hypergly-
caemia was present in almost all patients but that it was not
associated with increased incidence of postoperative infec-
tions and length of hospital stay.
Van den Berghe and coworkers [1] found that lowering post-
operative hyperglycaemia with intensive insulin therapy signif-
icantly decreased morbidity and mortality in postoperative
patients. Post hoc analysis revealed that both administration of
insulin and, possibly to a greater degree, lower glucose levels
contributed to better outcome [11]. However, it is unclear how
the effect of intensive insulin therapy in surgical intensive care
patients can be explained and which patient groups benefit
most from intensive insulin therapy. We propose the following
explanation for the seemingly contradictory findings of our
study.
The population evaluated in the study by van den Berghe and
coworkers [1] consisted mainly of patients undergoing cardio-
vascular surgery. Transient or 'stress induced' hyperglycaemia
was previously reported to be associated with a poor progno-
sis, primarily in patients with obstructive vascular disease such
as those with acute myocardial infarction and acute stroke,
and in those who have undergone cardiovascular bypass sur-
gery and peripheral vascular surgery [12-16]. Few patients in
our cohort suffered from (cardio)vascular disease because
ASA class 1 or 2 was a prerequisite for inclusion in the study,
and only 11% had a history of coronary artery disease. It could
thus be hypothesized that, in a population with little vascular
disease, high postoperative glucose levels are not associated
with poor outcome.
In response to surgery, both plasma glucose levels and free
fatty acid (FFA) levels rise [17]. Pathophysiological mecha-
nisms that may explain the relationship between stress
Table 2
Multivariate analysis of infectious complications
Prognostic variable OR (95% CI) P
FEV1 (per 10% of expected FEV1) 0.79 (0.63–0.99) 0.045
History of cardiac valve disease or arrhythmia 7.30 (0.78–68.3) 0.081
Duration of surgery 1.27 (0.98–1.64) 0.069
Age per 10 years 1.36 (0.90–2.07) 0.142
Mean postoperative glucose 1.21 (0.86–1.72) 0.279
CI, confidence interval; FEV1, forced expiratory volume in 1 s; OR, odds ratio.
Figure 1
Percentage of (a) infections and (b) median length of hospital stay per  glucose quartile Percentage of (a) infections and (b) median length of hospital stay per 
glucose quartile: first quartile 5.2–7.4 mmol/l, second quartile 7.5–8.2 
mmol/l, third quartile 8.3–9.2 mmol/l, and fourth quartile 9.3–17.2 
mmol/l. The error bars in panel b represent the interquartile range.Available online http://ccforum.com/content/8/6/R437
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induced hypermetabolism and poor outcome in patients with
cardiovascular disease include the following: toxic effects of
elevated FFA levels on the ischaemic myocardium [18]; ele-
vated FFA levels and hyperglycaemia causing QT prolongation
[19]; hyperglycaemia attenuating ischaemic preconditioning
[20]; and hyperglycaemia causing reduced collateral coronary
perfusion [21]. Haemodynamic effects of glucose and insulin
may also play an important role in the pathophysiology of
stress induced hypermetabolism. Hyperglycaemia has vaso-
constrictive effects [22], which may aggravate tissue ischae-
mia, particularly in patients with obstructive vascular disease.
Insulin has been reported to have vasodilatory effects, and part
of the beneficial effect of intensive insulin therapy may be
explained by increasing tissue perfusion [23].
Our data do not exclude the possibility that intensive insulin
therapy or glucose–insulin–potassium infusions may still be
beneficial in this particular subgroup of patients. The benefits
of intensive insulin therapy may not solely be attributed to low-
ering hyperglycaemia, but may be mediated by the effect of
insulin on protein and lipid metabolism, independent of its
effects on glucose metabolism. In patients with sepsis and
cancer, lower levels of insulin are needed to restore lipid levels
than glucose levels [24]. Similarly, depleted protein storage
and severe surgical stress after oesophageal resection may
impair the immune response postoperatively and thus increase
the risk for postoperative infection [25], which may be amelio-
rated by insulin. However, the administration of insulin was not
associated with lower infection risk in our cohort.
A shortcoming of the present study is that the number of glu-
cose measurements taken in each patient was not standard-
ized, because of the study's retrospective design. For some
patients more glucose measurements were available than for
others, and this may have influenced our results. However, glu-
cose measurements were taken randomly with each arterial
blood gas analysis, and because mean postoperative glucose
levels were used, the relative weight of incidental extreme val-
ues was diminished. A strength of our cohort is its homogene-
ity. It represents a unique group of patients with high
postoperative stress and a low frequency of risk factors for
obstructive vascular disease.
Conclusion
Despite the limitations associated with the retrospective anal-
ysis of a prospective study, our data indicate that early postop-
erative hyperglycaemia is more likely to be a risk marker than a
risk factor in a patient group encountering severe surgical
stress but with a low prevalence of cardiovascular disease.
We therefore suggest that the value of intensive insulin ther-
apy, which is time consuming and potentially hazardous,
needs further investigation in this particular patient group.
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Table 3
Multivariate analysis of length of stay
Prognostic variable β SE of β P
Duration of surgery 0.062 0.021 0.004
BMI 0.010 0.006 0.072
Mean postoperative glucose 0.024 0.018 0.195
History of cardiac valve disease or arrhythmia 0.058 0.091 0.527
Transhiatal procedure 0.034 0.065 0.599
BMI, body mass index; SE, standard error.
Key messages
•  Postoperative hyperglycaemia after oesophagectomy 
was not found to be associated with postoperative 
infection risk.
•  Postoperative hyperglycaemia after oesophagectomy 
was found to be associated with longer duration of 
postoperative stay. However, when corrected for pos-
sible confounders, postoperative hyperglycaemia was 
not found to be an independent risk factor for longer 
duration of stay.
•  Strict glycaemic control may not be beneficial for 
patients after oesophagectomy.Critical Care    December 2004  Vol 8 No 6    Vriesendorp et al.
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